Schedule 13D ownership disclosure
Keros Therapeutics Inc
Common Stock, Par Value $0.0001 Per Share · CUSIP: 492327101
Event date: 2025-10-15
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Pontifax Management 4 GP (2015) Ltd.Reported CIK 0001726334
Shares: 0.00 · Class: 0%
- Pontifax (Israel) IV, L.P.
Shares: 0.00 · Class: 0%
- Pontifax (Cayman) IV, L.P.
Shares: 0.00 · Class: 0%
- Pontifax (China) IV, L.P.
Shares: 0.00 · Class: 0%
- Pontifax Late Stage Fund L.P.
Shares: 0.00 · Class: 0%
- Pontifax Late Stage GP Ltd.
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-002751
- Form type
- SCHEDULE 13D/A
- Filer
- Keros Therapeutics, Inc.
- CIK
- CIK 1664710
- Filed
- Oct 16, 2025
- Reporting period
- Oct 15, 2025
- Description
- Schedule 13D beneficial ownership